MeiraGTx Holdings: Gaining Regulatory Focus

Company Overview - MeiraGTx (NASDAQ: MGTX) focuses on developing genetic therapies for ocular diseases, Parkinson's Disease, and xerostomia [1] - The lead asset of the company is AAV-AQP1, which targets xerostomia and is currently in a pivotal phase 2 trial [1] Industry Insights - The company operates within the genetic therapy sector, which is increasingly gaining attention for its potential to address various chronic and debilitating conditions [1]